Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 06/22/12 → 11/18/16 |
Funding
- Boehringer Ingelheim Pharmaceutical: $57,638.82
A Randomized, Open-Label, Phase III Study to Evaluate the Efficacy of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who have Progressed After...
- Keresztes, Roger (PI)
- Kudelka, Andrzej (CoPI)
Project: Research